Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7Sarcoma 6Lymphoid 6Genitourinary 6Tumor-Agnostic 4Plasma cell 4Other hematologic neoplasm 4CNS 3Thoracic 2Other solid neoplasm 2Myeloid 2Gynecologic 2Breast 2Head & Neck 1Dermatologic 1

Conditions

Melanoma 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
perifosine × Dermatologic × Clear all
NCT00053781 2023-08-04

Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Canadian Cancer Trials Group

Phase 2 Completed
18 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡